精品国产污网站在线看_亚洲国产中文在线_欧洲亚洲免费旡码_亚洲中文自拍另类av片

Introduction to investment promotion

一、Company Overview

Shanghai Jin Emperor (Anyang) Co., Ltd. formerly known as Anyang Jiuzhou Pharmaceutical Co., Ltd., is a key pharmaceutical company in Anyang City, Henan Province. It was relocated in Tangyin County from Wenfeng District, Anyang City in July 2009. Industrial cluster area (Pharmaceutical Industrial Park) Bianque Road, the company covers an area of 130 acres, registered capital of 80 million yuan, fixed assets of 220 million yuan, total assets of 250 million yuan. The main products include antibiotic raw materials, synthetic raw materials, small-volume injections, 82 series of approvals, more than 90 varieties, the products are exported to Southeast Asia, Africa, Europe and other countries and regions, enjoying high reputation in the international and domestic markets. It is a “high-tech enterprise in Henan Province”, “a key taxpayer of 100 households in Anyang City”, and “50-year high enterprise in Anyang City in 2013”. In 2014, it was awarded a credit enterprise by the Tangyin County Government.

The company's three series of drugs: antibiotic raw materials, synthetic raw materials, small-volume injections have passed the 2010 version of the drug quality GMP certification; investment of more than 26 million yuan to build three waste (waste water, waste gas, waste residue) treatment of environmental protection facilities, wastewater treatment capacity of 600 tons, The waste slag is treated for 12 tons per day. In October 2016, it passed the technical review of Henan environmental protection experts and was awarded the EIA certificate. The company now has complete water, electricity, steam, wind, cold power and environmental protection, quality inspection, animal laboratory and other supporting equipment. Equipment and facilities; the company has convenient transportation. The industrial park where the factory is located is adjacent to Beijing-Guangzhou Railway, Beijing-Zhuhai Expressway and high-speed railway. The enterprises in the medical park have long enjoyed preferential policies for attracting investment from government services.

二﹑Current production and operation of the company and development plan

(1) Small volume injection:Obtained 75 approval numbers. The production capacity of single shift is 50 million pieces/month, the output value is 800-9 million yuan/month, and the annual output value is 100 million yuan. In order to give full play to the advantages of multiple products and complete batches of documents, timely adjust marketing strategies and increase market share. According to the company's small-volume injections, the sales target of 300 million yuan is constantly expanding and expanding. The first step is to expand production, and the single-shift production will become double-shift production. The monthly output will reach 90 million, the output value will reach 15-16 million yuan/month, the annual output will be 1 billion, and the output value will be 1.5-160 million yuan. The profit is 16 million yuan. The second step is to build a new workshop, invest 30 million yuan, build a small-volume injection workshop with two production lines, increase annual output by 500 million, output value of 150 million yuan, and profit of 16 million yuan. The third step is to optimize the products and make the unique varieties better and increase the high profits. Such as: Hydroxylcobalamin hydrochloride, the domestic one of my family has approved, and now we are reporting the approval of the unique drug substance: Hydroxylcobalamin hydrochloride. The company will continue to play the role of raw materials, injections have the unique advantages of approval, further optimize the process, and make the unique products better and stronger.

(2) Antibiotic bio-fermentation drugs:Our company has a biological fermentation workshop with a total volume of 816 cubic meters, and the extraction process is advanced. It can produce a variety of bio-fermentation products, and has already possessed the capacity of “one end and many tails”; it is currently cooperating with Suzhou Hi-Tech Biotech Co., Ltd., using the company's advanced production platform to upgrade new products while producing, and can achieve annual profit increase target. The company's total fermentation volume is still 400 cubic meters to be externally cooperated; the company has successfully developed and researched the biological fermentation varieties: sodium hyaluronate, cyclic adenosine monophosphate, glutathione, etc., which are the new economic growth points of the company. product.

(3) Chemical synthesis drugs:The company has three workshops for chemical synthesis drugs. The varieties are: diclofenac sodium, diclofenac potassium, hydrochlorothiazide, cinnarizine, nitrendipine, propafenone hydrochloride. The research and development is being carried out: Hydroxahydrochloramine hydrochloride, acetazolamide bulk drug.

三、Foreign cooperation intention

The company intends to cooperate with the outside world in three aspects:

(I) Product cooperation intention: Our company is willing to carry out extensive cooperation with well-known medical research institutions. The cooperation direction is as follows:

First, relying on the fermentation plant platform and technology, introducing new varieties of bio-fermentation raw materials such as antibiotics, as well as bio-fermentation veterinary drugs and pesticides.

Secondly, relying on the advantages of the three synthetic production workshops of five varieties of diclofenac sodium raw materials, the company further explores the international and domestic markets, and hopes to cooperate in the development of new synthetic raw material products (the production area can be constructed with 500 square meters of open space) A dozen workshops).

Third, we want to seek to join large-scale pharmaceutical companies (groups) at home and abroad, relying on group companies to expand the production scale of small-capacity injections, promote market sales, introduce new varieties of high-value-added injections, and enhance the cooperation and win-win between the two companies' brands.

Fourth, jointly carry out product development, workshop construction, production and sales management of hyaluronic acid and cyclic adenosine monophosphate, and exert their respective advantages to achieve mutual benefit and win-win.

(2) The company has idle land and can build 7 to 8 production workshops of 1500 square meters.

(3) Various forms of cooperation intentions:

After the whole workshop of our company is put into production, it is estimated that the annual sales income will be 350 million yuan, and the profit and tax will be more than 40 million yuan. In order to speed up the pace of transformation and upgrading, increase new economic growth points, and further strengthen and expand the enterprise, the shareholders' meeting decided to introduce funds in various forms, and plans to cooperate with large and powerful pharmaceutical companies and people with knowledge and wisdom. The method can be specifically agreed, such as acquisition, holding, capital increase or capital increase, with projects, and adopt a variety of cooperation methods. Exhibitions and plans to make good medicines and cohesive forces to benefit the well-being of the people, and create a great career to create a golden glory to achieve the Kyushu take-off! Zhao Wenwu, the chairman of the company, and all the shareholders, warmly welcome domestic and foreign knowledgeable and intelligent people to come to our company to invest in the industry and seek common development!

Shanghai Jin Emperor (Anyang) Co., Ltd.   Chairman Zhao Wenwu 13903727767  General Manager Zhang Lixia 13603468686

Address: Bianbu Road, Tangyin Industrial Cluster, Henan Province     Code：456150

Tel：0372—6250880   Email：JZ6250890@126.com   Fax：6250890    URL;www.undertheinkfluence.com